Comparison between effects of myo-inositol and d-chiro-inositol on ovarian function and metabolic factors in women with PCOS

References

• Azziz R, Woods KS, Reyna R, et al. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004;89:2745–9
   PubMed Web of Science ®Google Scholar
• Norman RJ, Dewailly D, Legro RS, Hickey TE. Polycystic ovary syndrome. Lancet 2007;370:685–97
   PubMed Web of Science ®Google Scholar
• Kurdoglu Z, Ozkol H, Tuluce Y, Koyuncu I. Oxidative status and its relation with insulin resistance in young non-obese women with polycystic ovary syndrome. J Endocrinol Invest 2012;35:317–21
   PubMed Web of Science ®Google Scholar
• González F, Rote NS, Minium J, Kirwan JP. Reactive oxygen species-induced oxidative stress in the development of insulin resistance and hyperandrogenism in polycystic ovary syndrome. J Clin Endocrinol Metab 2006;91:336–40
   PubMed Web of Science ®Google Scholar
• Franks S. Polycystic ovary syndrome: a changing perspective. Clin Endocrinol (Oxf) 1989;31:87–120
   PubMed Web of Science ®Google Scholar
• James RG, Krakower GR, Kissebah AH. Influence of androgenicity on adipocytes and precursor cells in female rats. Obes Res 1996;4:463–70
   PubMedGoogle Scholar
• Schuring AN, Schulte N, Sonntag B, Kiesel L. Androgens and insulin – two key players in polycystic ovary syndrome. Recent concepts in the pathophysiology and genetics of polycystic ovary syndrome. Gynakol Geburtshilfliche Rundsch 2008;48:9–15
   PubMedGoogle Scholar
• Norman RJ, Clark AM. Lifestyle factors in the aetioloy and management of polycystic ovary syndrome. In: Kovacs GT, ed, Polycystic ovary syndrome. 1st ed. Cambridge: Cambridge University Press; 2000, pp. 98--116
   Google Scholar
• Kuşçu NK, Var A. Oxidative stress but not endothelial dysfunction exists in non-obese, young group of patients with polycystic ovary syndrome. Acta Obstet Gynecol Scand 2009;88:612–7
   PubMed Web of Science ®Google Scholar
• Azziz R. Androgen excess is the key element in polycystic ovary syndrome. Fertil Steril 2003;80:252–4
   PubMed Web of Science ®Google Scholar
• Ehrmann DA, Barnes RB, Rosenfield RL, et al. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 1999;22:141–6
   PubMed Web of Science ®Google Scholar
• Landay M, Huang A, Azziz R. Degree of hyperinsulinemia, independent of androgen levels, is an important determinant of the severity of hirsutism in PCOS. Fertil Steril 2009;92:643--7
   Google Scholar
• Cheang KI, Baillargeon JP, Essah PA, et al. Insulin-stimulated release of d-chiro-inositol-containing inositolphosphoglycan mediator correlates with insulin sensitivity in women with polycystic ovary syndrome. Metabolism 2008;57:1390–7
   PubMed Web of Science ®Google Scholar
• Genazzani AD, Lanzoni C, Ricchieri F, Jasonni VM. Myoinositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndrome. Gynecol Endocrinol 2008;24:139–44
   PubMed Web of Science ®Google Scholar
• Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004;19:41–7
   PubMed Web of Science ®Google Scholar
• Costantino D, Minozzi G, Minozzi E, Guaraldi C. Metabolic and hormonal effects of myo-inositol in women with polycystic ovary syndrome: a double-blind trial. Eur Rev Med Pharmacol Sci 2009;13:105–10
   PubMed Web of Science ®Google Scholar
• Papaleo E, Unfer V, Baillargeon JP, Chiu TT. Contribution of myo-inositol to reproduction. Eur J Obstet Gynecol Reprod Biol 2009;147:120–3
   PubMed Web of Science ®Google Scholar
• Nordio M, Proietti E. The combined therapy with myo-inositol and d-chiro-inositol reduces the risk of metabolic disease in PCOS overweight patients compared to myo-inositol supplementation alone. Eur Rev Med Pharmacol Sci 2012;16:575–81
   PubMed Web of Science ®Google Scholar
• Nestler JE, Jakubowicz DJ, Reamer P, et al. Ovulatory and metabolic effects of d-chiro-inositol in the polycystic ovary syndrome. N Engl J Med 1999;340:1314–20
   PubMed Web of Science ®Google Scholar
• Iuorno MJ, Jakubowicz DJ, Baillargeon JP, et al. Effects of d-chiroinositol in lean women with the polycystic ovary syndrome. Endocr Pract 2002;8:417–23
   PubMedGoogle Scholar